AVROBIO, Inc. (NASDAQ:AVRO – Get Rating) has been assigned an average rating of “Buy” from the nine research firms that are presently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $5.29.
AVRO has been the subject of a number of analyst reports. Zacks Investment Research lowered AVROBIO from a “buy” rating to a “hold” rating in a research report on Thursday, May 12th. Wedbush lowered their target price on shares of AVROBIO from $14.00 to $4.00 in a report on Wednesday, May 11th. Finally, Barclays cut their price target on shares of AVROBIO from $6.00 to $4.00 in a report on Wednesday, May 11th.
AVRO opened at $0.96 on Friday. AVROBIO has a fifty-two week low of $0.74 and a fifty-two week high of $11.00. The company has a debt-to-equity ratio of 0.10, a quick ratio of 9.98 and a current ratio of 9.98. The company’s 50-day moving average is $1.08 and its 200 day moving average is $2.13.
A number of hedge funds have recently made changes to their positions in AVRO. Point72 Hong Kong Ltd bought a new position in AVROBIO during the third quarter valued at $26,000. Mirabella Financial Services LLP bought a new position in shares of AVROBIO during the 1st quarter worth $42,000. Penn Mutual Asset Management LLC purchased a new stake in AVROBIO in the 1st quarter worth about $49,000. BNP Paribas Arbitrage SA raised its stake in AVROBIO by 112.5% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 9,665 shares of the company’s stock valued at $54,000 after acquiring an additional 5,117 shares during the period. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in AVROBIO during the third quarter valued at about $63,000. 63.92% of the stock is currently owned by institutional investors and hedge funds.
AVROBIO Company Profile (Get Rating)
AVROBIO, Inc, a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease.
- Get a free copy of the StockNews.com research report on AVROBIO (AVRO)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
Receive News & Ratings for AVROBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVROBIO and related companies with MarketBeat.com's FREE daily email newsletter.